NYSE - Nasdaq Real Time Price USD

Teva Pharmaceutical Industries Limited (TEVA)

Compare
18.00 -0.18 (-0.96%)
As of 10:50 AM EDT. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
16,289,000.00
15,845,000.00
14,925,000.00
15,879,000.00
16,658,000.00
--
Cost of Revenue
8,227,000.00
8,200,000.00
7,952,000.00
8,284,000.00
8,933,000.00
--
Gross Profit
8,062,000.00
7,645,000.00
6,973,000.00
7,594,000.00
7,726,000.00
--
Operating Expense
4,564,000.00
4,451,000.00
4,283,000.00
4,495,000.00
4,668,000.00
--
Operating Income
3,498,000.00
3,194,000.00
2,690,000.00
3,099,000.00
3,058,000.00
--
Net Non Operating Interest Income Expense
-1,058,000.00
-1,095,000.00
-991,000.00
-962,000.00
-963,000.00
--
Other Income Expense
-2,583,000.00
-2,723,000.00
-4,859,000.00
-1,480,000.00
-6,500,000.00
--
Pretax Income
-142,000.00
-624,000.00
-3,163,000.00
658,000.00
-4,406,000.00
--
Tax Provision
606,000.00
-7,000.00
-643,000.00
211,000.00
-168,000.00
--
Earnings from Equity Interest Net of Tax
-1,000.00
2,000.00
21,000.00
9,000.00
138,000.00
--
Net Income Common Stockholders
-453,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
--
Diluted NI Available to Com Stockholders
-453,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
--
Basic EPS
-0.39
-0.50
-2.12
0.38
-3.64
--
Diluted EPS
-0.39
-0.50
-2.12
0.38
-3.64
--
Basic Average Shares
1,124,000.00
1,119,000.00
1,110,000.00
1,102,000.00
1,095,000.00
--
Diluted Average Shares
1,124,000.00
1,119,000.00
1,110,000.00
1,107,000.00
1,095,000.00
--
Total Operating Income as Reported
877,000.00
433,000.00
-2,197,000.00
1,716,000.00
-3,572,000.00
--
Total Expenses
12,791,000.00
12,651,000.00
12,235,000.00
12,779,000.00
13,601,000.00
--
Net Income from Continuing & Discontinued Operation
-453,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
--
Normalized Income
1,527,440.00
2,122,910.00
1,420,400.00
1,409,503.04
1,427,664.00
--
Interest Expense
992,000.00
1,029,000.00
930,000.00
891,000.00
901,000.00
--
Net Interest Income
-1,058,000.00
-1,095,000.00
-991,000.00
-962,000.00
-963,000.00
--
EBIT
850,000.00
405,000.00
-2,233,000.00
1,549,000.00
-3,505,000.00
--
EBITDA
1,930,000.00
1,558,000.00
-925,000.00
2,879,000.00
-1,948,000.00
--
Reconciled Cost of Revenue
8,227,000.00
8,200,000.00
7,952,000.00
8,284,000.00
8,933,000.00
--
Reconciled Depreciation
1,080,000.00
1,153,000.00
1,308,000.00
1,330,000.00
1,557,000.00
--
Net Income from Continuing Operation Net Minority Interest
-453,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
--
Total Unusual Items Excluding Goodwill
-2,572,000.00
-2,709,000.00
-4,833,000.00
-1,461,000.00
-6,496,000.00
--
Total Unusual Items
-2,572,000.00
-2,709,000.00
-4,833,000.00
-1,461,000.00
-6,496,000.00
--
Normalized EBITDA
4,502,000.00
4,267,000.00
3,908,000.00
4,340,000.00
4,548,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-591,560.00
-27,090.00
-966,600.00
-468,496.96
-1,078,336.00
--
12/31/2019 - 2/16/1982

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers